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Resveratrol, a natural polyphenol, has numerous biological activities such as anticancer, 
antioxidant, anti-inflammatory. Resveratrol is highly oxidisable due to its chemical structure, 
and reacts with reactive oxygen species or free radicals resulting in new metabolites that are 
also potentially bioactive. Oxidation of resveratrol in various conditions resulted in mixtures 
that exhibited greater lipoxygenase inhibitory activities compared to the parent compound. 
This, together with the complex chromatographic fingerprints of the mixtures suggests that 




Resveratrol is a well-known polyphenol with plethora of pharmacological activities such as 
anticancer, antioxidant, anti-inflammatory, cardio-protective and neuroprotective [1,2]. Most 
polyphenols are not stable, especially under oxidative conditions and often lead to the 
accumulation of new metabolites in living systems [3]. These new metabolites have been 
suggested to mediate at least some biological effects of the parent compound [4]. One of such 
studies showed a greater lipoxygenase (LOX) inhibitory activity of Fe-catalyzed oxidation of 
resveratrol and led to the identification of some active metabolites that, however, did not fully 
explain the increase in bioactivity [5]. 
LOX accelerates lipid oxidation by converting arachidonic, linoleic and other polyunsaturated 
fatty acids into biologically active metabolites, which are implicated in the pathogenesis of a 
variety of human diseases. Therefore, it is a promising therapeutic target for the prevention  
and/or treatment of a wide spectrum of human diseases [6]. 
Thus, we aimed at preparing oxidized resveratrol metabolites through various chemical 
reactions including biomimetic approaches, and to study the lipoxygenase inhibitory activity 
of the mixtures obtained. 
 
Experimental 
Resveratrol with a purity 97%, was purchased from Career Henan Chemical Co., China. 
Several oxidative reactions were carried out on resveratrol as shown in Table 1. The reactions 
were monitored by TLC at regular intervals. At the end of each reaction, the mixtures were 
evaporated, extracted with ethyl acetate and evaporated. As a prepurification step, each 
residue was filtrated through silica with hexane – acetone (1:1, v/v). A ten microliters aliquot 
of each mixture dissolved in CH3CN was analized by HPLC (PU-2080 pumps; AS-2055 Plus 
autosampler; MD-2010 Plus PDA detector, Jasco Co., Tokyo, Japan) under the following 
conditions: column, Kinetex XB-C18 (250 x 4.6mm, 5μ); solvent system, water (solvent A) 
and CH3CN (solvent B): elution, linear gradient from 25% solvent B to 75% solvent B for 25 
min and then isocratic mode for 75% solvent B for 2 min; flow rate, 1mlmin
-1
; detection, 
199nm – 650nm. 
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Table 1: Oxidative conditions applied on resveratrol. 
 
Lipoxygenase inhibition of the reaction mixtures was determined using the Lipoxygenase 
Inhibition Screening Assay Kit (760700, Cayman Chemical, USA) according to the leaflet 
instructions, with absorbance measured using a plate reader (BMG Lambtech GmbH, 
Germany) 
Percentage inhibition was calculated as;    
       % inhibition = (IA – inhibitor)/IA x 100 
IA = absorbance of the  100% initial activity wells (containing LOX and solvent used to 
dissolve the reaction mixtures). 
Inhibitor = absorbance of the inhibitor wells (containing LOX and reaction mixture). 
 
Results and discussion 
Results show resveratrol had little or no inhibitory activity on 15-LOX, which corroborates 
several reports [5]. Lipoxygenase is a key pro-inflammatory enzyme with a central role in 
various diseases; therefore, lipoxygenase inhibitors have attracted much interest in medical 
science [7]. Our data indicated that various oxidized resveratrol mixtures exhibited significant 
activities while resveratrol itself was inactive. Similar increase in the increased LOX 
inhibitory following Fe-catlaysed oxidation was found as previously reported [5]. In our case, 
mixtures obtained with periodic acid and iodine exerted the greatest LOX inhibitory activities 
that were ca. 50% at 4mM concentration; chromatographic fingerprints of these samples are 
shown in Figure 1.  
 
ID Oxidants Experimental conditionsa 
Rox1 2 eq. (Diacetoxyiodo)benzene (PIDA) EtOH, r.t., 2h 
Rox2 2 eq. (Diacetoxyiodo)benzene (PIDA) CH3CN, r.t., 5h 
Rox3 1 eq. (Bis(trifluoroacetoxy)iodo)benzene (PIFA) EtOH, r.t., 2h 
Rox4 1 eq. (Bis(trifluoroacetoxy)iodo)benzene (PIFA) CH3CN, r.t., 5h 
Rox5 1.5eq. (Diacetoxyiodo)benzene (PIDA) CH3CN, r.t., 2h 
Rox6 1 eq. 2,2'-Azobis(2-amidinopropane) dihydrochloride  EtOH, 65°C, 72hc 
Rox7 1.5 eq. 2,2'-Azobis(2-amidinopropane) 
dihydrochloride, 1 eq sodium periodate 
EtOH/H2O(3:1), 65°C, 
24hc 
Rox8 1.5eq. 2,2'-Azobis(2-amidinopropane) 
dihydrochloride, 10eq hydrogen peroxide 
EtOH/H2O (2:1), 65°C, 
24hc 
Rox9 1 eq. Iodine EtOH/H2O  (1:1), r.t, 24h
b 
Rox10 2 eq. Iodine EtOH/H2O  (1:1), r.t. 24h
b 
Rox11 1 eq. periodic acid EtOH/H2O  (3:1), r.t, 24h
b 
Rox12 2 eq. 2,2-diphenyl-1-picrylhydrazyl (DPPH) EtOH, dark/r.t., 0.5h 
Rox13 2 eq. 2,2-diphenyl-1-picrylhydrazyl (DPPH) CH3CN, dark/r.t., 0.5h 
Rox14 2 eq. 2,2-diphenyl-1-picrylhydrazyl (DPPH) MeOH, dark/r.t., 0.5h 
Rox15 0.001 eq. FeCl3 EtOH, r.t., 20 days 
Rox16 0.01 eq. FeCl3 EtOH, r.t., 20 days 
Rox17 0.31eq. iron (III) meso-tetra (p-hydroxyphenyl) 
porphine chloride, 10eq, hydrogen peroxide 
MeOH/Acetate buffer 
(4:1) r.t., 48h 
a
Experimental conditions are given as solvent, temperature, time, respectively. 
b
reactions were stopped using aq. sodium thiosulfate 
c
reactions were stopped using ice-bath. 
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Figure 1. HPLC fingerprint of samples ROX9 and ROX11 that exerted near 50% inhibition of 
LOX in our experimental setup, while their parent compound resveratrol was inactive at the 
same concentration. 
 
We plan to perform metabolomic studies of the reaction mixtures in the near future to assist 
the identification of compounds with a high LOX inhibitory potential. 
Previously, resveratrol was found to moderately inhibit cell proliferation and viability in 
MCF-7 and MDA-MB-231 cancer cell lines [8,9]. Evaluation of the anti-proliferative 
activities of the oxidized resveratrol mixtures is currently ongoing. 
 
Conclusion 
The oxidation of resveratrol led to the accumulation of metabolites that showed favorable 
LOX inhibitory as compared to the parent compound. Isolation and purification of the 
individual metabolites in these complex oxidized mixtures could result in the discovery of 
compounds with potentially greater pharmacological activity. 
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